NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

YD Bio Ltd (YDES) Stock Analysis

YD Bio Ltd (YDES) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

YDES

$3.54

−$0.13 (−3.54%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare YDES with… →

YDES Key Statistics

As of Sep 4, 2026
Trading
Open
$3.67
Previous Close
$3.67
Day's Range
3.29–3.88
52-Week Range
1.70–25.00
Volume
687.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.03
Valuation
Market Cap
$250.74M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
491.31
EPS (ttm)Profit attributable to each share over the last twelve months.
0.00
Financials (FY)
Revenue (FY)
$596.82K+16.94%
Net Income (FY)
−$8.31M
Profit marginThe share of revenue left as profit after all costs and taxes.
−276.58%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
70.83M
1-Year Return
−75.97%
Dividend and dates
Avg Volume
184.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

YDES Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−70.96%
2025 (partial year)−8.76%

As of September 4, 2026.

YDES Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$596.82K−$8.31M−1392.6%
2024$510.36K−$1.41M−276.6%
2023$350.13K$13.56K3.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$596.82K$167.41K−$5.27M−$8.31M−1392.6%
2024$510.36K$155.36K−$1.46M−$1.41M−276.6%
2023$350.13K$153.45K−$7.12K$13.56K3.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

YDES Valuation vs Biotechnology Median

Median of 656 stocks
MetricYDESBiotechnology medianvs median
P/S ratio491.3115.2632.2x the median
Profit margin−276.58%0.00%276.6 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

YD Bio Ltd (YDES) is capitalised at $250.74M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector.

The most recent close on file for YDES is $3.54, dated September 4, 2026. That is −$0.13 (−3.54%) against the previous close. Over the past 52 weeks the price has ranged from $1.70 to $25.00. The latest close sits 108.24% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $596.82K. That is +16.94% against the prior fiscal year, when revenue was $510.36K. The same year closed with a net loss of $8.31M. The reported profit margin is −276.58%. That is 276.6 percentage points below the Biotechnology median of 0%. Trailing earnings per share are 0.

Across the 3 fiscal years on file, revenue moves from $350.13K in 2023 to $596.82K in 2025. Of those 3 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 491.31. On price-to-sales that is 32.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at −0.03. Annualized volatility over the trailing 1 year is 123.16%. The trailing one-year price return is −75.97%.

Growth & Income

The record shows no dividend for YDES.

So far in 2026 the price is −70.96%.

Peer Comparison

YD Bio Ltd (YDES) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
YD Bio Ltd YDES $250.74M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. YD Bio Ltd has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About YD Bio Ltd

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

Visit website →